FDA Adverse Event Malfunction Summary report: N

BD VACUTAINER® BLOOD ALCOHOL DETERMINATIONS SODIUM FLUORIDE: POTASSIUM OXALATE

MDR report key: 8730842 · Received June 25, 2019

Report

Report Number
1917413-2019-01638
Event Type
Malfunction
Date Received
June 25, 2019
Date of Event
June 3, 2019
Report Date
July 18, 2019
Manufacturer
BECTON, DICKINSON & CO. (BROKEN BOW)
Product Code
JKA
UDI-DI
50382903670012
PMA / PMN Number
K901449
Removal / Correction Number
PAS-19-1461
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
TX, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 0

ADDITIONAL INFORMATION: H.7. REMEDIAL ACTION REQUIRED: THIS INFORMATION IS ASSOCIATED WITH FIELD ACTION # 2243072-05/09/2019-008-R 1. RECALL SUMMARY BD IS CONDUCTING A VOLUNTARY MEDICAL DEVICE RECALL FOR THE BD VACUTAINER® FLUORIDE TUBES FOR BLOOD ALCOHOL DETERMINATIONS, CATALOG# 367001, LOT #8187663. THE RECALLED LOT HAS BEEN CONFIRMED TO HAVE NO ADDITIVE WITHIN THE TUBE. 2. PRODUCT AND SCOPE BD VACUTAINER® FLUORIDE TUBES FOR BLOOD ALCOHOL DETERMINATIONS. 3. DESCRIPTION OF ISSUE THE RECALLED LOT HAS BEEN CONFIRMED TO HAVE NO ADDITIVE WITHIN THE TUBE (SEE INVESTIGATION SUMMARY BELOW FOR SCOPING DETAILS). BD PAS IDENTIFIED THIS ISSUE THRU THE BD COMPLAINT INVESTIGATION SYSTEM. 4. SUMMARY TABLE OF THE # OF COMPLAINTS AND MDRS IN SCOPE PER 806 # 2243072-05/09/2019-008-R DATED (B)(6), 2019, THERE WERE A TOTAL OF 2 COMPLAINTS AND 2 MDRS WITHIN SCOPE: COMPLAINT: (B)(4) / MDR: 1917413-2018-04055 COMPLAINT:(B)(4)0 / MDR: 1917413-2018-04112 5. HHE SUMMARY THE DEFECT FOR THIS PRODUCT IS RELATIVELY VISIBLE, AND FOLLOWING CLSI RECOMMENDED CLINICAL PRACTICE, THE PRODUCT WOULD BE INSPECTED PRIOR TO USE AND NOT BE USED FOR TESTING. HOWEVER, IF THE DEFECTIVE PRODUCT WAS USED FOR TESTING IT IS CRUCIAL TO BE ABLE TO STATE WITH CONFIDENCE THAT A REPORTED AMOUNT OF ALCOHOL WAS, IN FACT, PRESENT. IF COLLECTED AND TESTED, THE TUBES LACKING THE ADDITIVES, WILL ESSENTIALLY YIELD A CLOTTED SAMPLE THAT WOULD BE REJECTED. IF THESE SAMPLES DID GET TESTED, LITERATURE STATES THAT SAMPLES WITHOUT THIS PRESERVATIVE HAVE YIELDED RELIABLE RESULTS FOR SAMPLES STORED AT ROOM TEMPERATURE (25OC) FOR 2 DAYS. THE PATIENT WOULD BE TREATED BASED ON THEIR CLINICAL PICTURE AS PER CLINICAL PRACTICE, REGARDLESS OF THE RESULT WHEN THE PATIENT'S CLINICAL STATUS IS ASSESSED. IN CASE THE CLOTTED SAMPLES WERE NOT REJECTED AND SERUM WAS INADVERTENTLY TESTED AFTER 2 DAYS, THERE MAY BE A REMOTE CHANCE OF ERRONEOUS RESULTS, HOWEVER TREATMENT IS NOT DEPENDENT ON THE RESULT. ALSO, THE CHANCE OF BLOOD ALCOHOL TESTING AFTER TWO DAYS IS UNLIKELY. SINCE ALCOHOL RESULTS FROM SERUM SAMPLES LACK FORENSIC VALUE, CLOTTED SAMPLES WOULD NOT BE SUITABLE FOR TESTING DUE TO THE ABSENCE OF A RELIABLE CONVERSION FACTOR FROM SERUM TO WHOLE BLOOD. THEREFORE THE RESULTS COULD NOT BE USED FOR LEGAL REASONS. THE OVERALL HEALTH RISK ASSOCIATED WITH THIS DEFECT IS CONSIDERED VERY LOW. 6. INVESTIGATION SUMMARY DHR REVIEW WAS PERFORMED AND FOUND NO ISSUES WITH THE PRODUCT IN SCOPE. EVALUATION OF 200 TOTAL COMPLAINT SAMPLES VISUALLY CONFIRMED ¿INCORRECT ADDITIVE QUANTITY¿. ADDITIONALLY, 100 RETAIN SAMPLES FROM LOT 8187663 WERE EVALUATED, THESE SAMPLES DID NOT INDICATE ¿INCORRECT ADDITIVE QUANTITY¿. ALL PROCESS AND FINAL INSPECTIONS COMPLY WITH SPECIFICATION REQUIREMENTS. SUBSEQUENTLY, VIDEO FOOTAGE AT THE FILLING OPERATION WAS REVIEWED, IT WAS CONFIRMED THAT A 300 TUBE BATCH TRAY WAS INADVERTENTLY REMOVED FROM THE LINE PRIOR TO THE POWDER FILLING DISPENSING OPERATION, THIS UNFILLED TRAY WAS THEN PLACED ONTO A PALLET WITH POWDER FILLED PRODUCT. BD PAS HAS INITIATED CAPA 842998 TO FURTHER INVESTIGATE THIS ISSUE AND IMPLEMENT CORRECTIVE ACTIONS. 7. RECALL REFERENCE #, EITHER BD INTERNAL OR RES/Z# -PLEASE REFERENCE BD RECALL #(B)(4).

Additional Manufacturer Narrative · 0

H.6. INVESTIGATION SUMMARY: THIS COMPLAINT IS UNDER THE SCOPE OF FIELD ACTION # (B)(4). BD HAD NOT RECEIVED SAMPLES OR PHOTOS FROM THE CUSTOMER FACILITY FOR EVALUATION; THEREFORE, THE INVESTIGATION WAS LIMITED. A REVIEW OF THE DEVICE HISTORY RECORD WAS COMPLETED FOR THE INCIDENT LOT AND, BASED ON THIS REVIEW, ALL PRODUCT SPECIFICATIONS AND REQUIREMENTS FOR LOT RELEASE WERE MET; THERE WERE NO RELATED QUALITY NON-CONFORMANCES DURING MANUFACTURING OF THE PRODUCT. BD HAS INITIATED FURTHER INVESTIGATION RELATING TO THIS ISSUE THROUGH A CAPA AND POTENTIAL CAUSES HAVE BEEN IDENTIFIED. AS A RESULT, CORRECTIVE ACTIONS HAVE BEEN ESTABLISHED AND ARE IN THE PROCESS OF BEING IMPLEMENTED. AS NO SAMPLES OR PHOTOS WERE RECEIVED FOR EVALUATION, THE CUSTOMER'S INDICATED FAILURE MODE WAS NOT OBSERVED BY BD. HOWEVER, FURTHER INVESTIGATION ACTIVITIES HAVE BEEN CONDUCTED THROUGH A CAPA AND THE MOST LIKELY ROOT CAUSE HAS BEEN IDENTIFIED. AS A RESULT, CORRECTIVE ACTIONS AND PROCEDURES ARE BEING IMPLEMENTED TO MITIGATE FURTHER OCCURRENCES. ALTHOUGH NO SAMPLES OR PHOTOS WERE AVAILABLE FOR EVALUATION, BD HAS INITIATED FURTHER INVESTIGATION THROUGH A CAPA. THE CAPA HAS IDENTIFIED THE MOST LIKELY ROOT CAUSES AND CORRECTIVE ACTIONS ARE IN THE PROCESS OF BEING IMPLEMENTED. CAPA 842998. BASED ON AN ASSESSMENT OF SEVERITY AND FREQUENCY, IT WAS DETERMINED THAT A CAPA IS REQUIRED AT THIS TIME IN ORDER TO DETERMINE THE ROOT CAUSE ASSOCIATED WITH THIS ISSUE. THE INVESTIGATION HAS IDENTIFIED POTENTIAL ROOT CAUSE(S) FOR THIS ISSUE AND CORRECTIVE ACTIONS ARE IN THE PROCESS OF BEING IMPLEMENTED.

Description of Event or Problem · 0

MATERIAL NO: 367001 BATCH NO:8187663 IT WAS REPORTED THAT AFTER USE OF THE BD VACUTAINER® BLOOD ALCOHOL DETERMINATIONS SODIUM FLUORIDE: 100MG POTASSIUM OXALATE: 20MG TUBES ARRIVED AT THE LABORATORY CLOTTED, AND WHOLE BLOOD TEST RESULTS HAD TO BE REPORTED QUALITATIVELY RATHER THAN QUANTITATIVELY. THIS COMPLAINT WAS CREATED TO CAPTURE THE 8TH OF 9 PATIENTS AFFECTED BY THIS EVENT. THE FOLLOWING INFORMATION WAS PROVIDED BY THE INITIAL REPORTER: "WE HAVE AT LEAST SEVEN DIFFERENT CASE SPECIMENS IN THIS SPECIFIC BATCH THAT HAVE ARRIVED CLOTTED WHICH MAKES TESTING DIFFICULT AND POTENTIALLY IMPOSSIBLE. WE REACHED OUT TO THE SUBMITTING AGENCIES AND THEY WERE ALL TAKEN FROM DIFFERENT COLLECTION SITES, SO THE ONLY THING IN COMMON WITH THIS PROBLEM WAS THE CATALOG AND BATCH NUMBER. BECAUSE OF THE CLOTTING, RESULTS HAD TO BE REPORTED QUALITATIVELY (I.E. PRESENT) RATHER THAN QUANTITATIVELY, AS WE ARE LEGALLY REQUIRED TO REPORT RESULTS OF WHOLE BLOOD. IT IS NOT CLEAR HOW THE CLOTTED SAMPLES WILL IMPACT THE IMPENDING CRIMINAL TRIALS."

Description of Event or Problem · 0

MATERIAL NO: 367001 BATCH NO:8187663 IT WAS REPORTED THAT AFTER USE OF THE BD VACUTAINER® BLOOD ALCOHOL DETERMINATIONS SODIUM FLUORIDE: 100MG POTASSIUM OXALATE: 20MG TUBES ARRIVED AT THE LABORATORY CLOTTED, AND WHOLE BLOOD TEST RESULTS HAD TO BE REPORTED QUALITATIVELY RATHER THAN QUANTITATIVELY. THIS COMPLAINT WAS CREATED TO CAPTURE THE 8TH OF 9 PATIENTS AFFECTED BY THIS EVENT. THE FOLLOWING INFORMATION WAS PROVIDED BY THE INITIAL REPORTER: "WE HAVE AT LEAST SEVEN DIFFERENT CASE SPECIMENS IN THIS SPECIFIC BATCH THAT HAVE ARRIVED CLOTTED WHICH MAKES TESTING DIFFICULT AND POTENTIALLY IMPOSSIBLE. WE REACHED OUT TO THE SUBMITTING AGENCIES AND THEY WERE ALL TAKEN FROM DIFFERENT COLLECTION SITES, SO THE ONLY THING IN COMMON WITH THIS PROBLEM WAS THE CATALOG AND BATCH NUMBER. BECAUSE OF THE CLOTTING, RESULTS HAD TO BE REPORTED QUALITATIVELY (I.E. PRESENT) RATHER THAN QUANTITATIVELY, AS WE ARE LEGALLY REQUIRED TO REPORT RESULTS OF WHOLE BLOOD. IT IS NOT CLEAR HOW THE CLOTTED SAMPLES WILL IMPACT THE IMPENDING CRIMINAL TRIALS."

Additional Manufacturer Narrative · 1

DATE OF EVENT: UNKNOWN. THE DATE RECEIVED BY MANUFACTURER HAS BEEN USED FOR THIS FIELD. DEVICE EVALUATED BY MFR: A DEVICE EVALUATION IS ANTICIPATED, BUT HAS NOT YET BEGUN. UPON COMPLETION OF THE INVESTIGATION, A SUPPLEMENTAL REPORT WILL BE FILED.

Description of Event or Problem · 1

MATERIAL NO: 367001, BATCH NO:8187663. IT WAS REPORTED THAT AFTER USE OF THE BD VACUTAINER® BLOOD ALCOHOL DETERMINATIONS SODIUM FLUORIDE: 100MG POTASSIUM OXALATE: 20MG TUBES ARRIVED AT THE LABORATORY CLOTTED, AND WHOLE BLOOD TEST RESULTS HAD TO BE REPORTED QUALITATIVELY RATHER THAN QUANTITATIVELY. THIS COMPLAINT WAS CREATED TO CAPTURE THE 8TH OF 9 PATIENTS AFFECTED BY THIS EVENT. THE FOLLOWING INFORMATION WAS PROVIDED BY THE INITIAL REPORTER: "WE HAVE AT LEAST SEVEN DIFFERENT CASE SPECIMENS IN THIS SPECIFIC BATCH THAT HAVE ARRIVED CLOTTED WHICH MAKES TESTING DIFFICULT AND POTENTIALLY IMPOSSIBLE. WE REACHED OUT TO THE SUBMITTING AGENCIES AND THEY WERE ALL TAKEN FROM DIFFERENT COLLECTION SITES, SO THE ONLY THING IN COMMON WITH THIS PROBLEM WAS THE CATALOG AND BATCH NUMBER. BECAUSE OF THE CLOTTING, RESULTS HAD TO BE REPORTED QUALITATIVELY (I.E. PRESENT) RATHER THAN QUANTITATIVELY, AS WE ARE LEGALLY REQUIRED TO REPORT RESULTS OF WHOLE BLOOD. IT IS NOT CLEAR HOW THE CLOTTED SAMPLES WILL IMPACT THE IMPENDING CRIMINAL TRIALS."

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
526176 BD VACUTAINER® BLOOD ALCOHOL DETERMINATIONS SODIUM FLUORIDE: POTASSIUM OXALATE BLOOD SPECIMEN COLLECTION DEVICE JKA BECTON, DICKINSON & CO. (BROKEN BOW) 8187663 50382903670012

Patients

Seq Age Sex Outcome Treatment
1 34 YR Other